Position of targeted therapy in ovariancancer management

Czech version

Authors: M. Majirský ¹; M. Kubecová ¹; E. Kindlová ¹; K. Tikovský ²
Authors‘ workplace: Radioterapeutická a onkologická klinika 3. LF UK a FN KV, Praha, přednostka doc. MUDr. M. Kubecová, Ph. D. ¹; Gynekologicko-porodnická klinika 3. LF UK a FN KV, Praha, přednosta doc. MUDr. E. Kučera, CSc. ²
Published in: Ceska Gynekol 2013; 78(4): 347-350

Overview

Ovarian cancer in Czech Republic takes first place in mortality among gynecological malignant tumours. In most cases it is diagnosed in advanced stages. Initial treatment is based on combination of radical surgery and adjuvant chemotherapy. In more than two thirds of cases ovarian cancer relapses sooner or later, very often without a chance to cure the patient. Unsatisfying result of standard treatment is reason of looking for more effective procedures. Targeted therapy is subject of research in last years. Positive effect of bevacizumab has been proved. Through inhibition of angiogenesis it leads to prolonging of interval to cancer progression.

Keywords:
ovarian cancer – targeted therapy – bevacizumab – QALY

Sources

1. Baluk, P., Hashizume, H., McDonald, DM., et al. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev, 2005.

2. Breckwoldt, M., Martius, G., Pfleiderer, A., et al. Gynekologie a porodnictví. Martin: Osveta, 1997, 648 s.

3. Burger, RA., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med, 2011, 365, p. 2473–2483.

4. Colombo, N., Peiretti, M., Parma, G., et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010, 21 (Supplemet 5), p. 23–30.

5. Folkman, J. Tumor angiogenesis: therapeutic implications. Review. N Engl J Med, 1971, 18, 285(21), p. 1182–1186.

6. Chovanec, J. Karcinom ovaria. Postgrad Med, 2012, 9, s. 71–78.

7. Klener, P., Klener, P. jr. Nová protinádorová léčiva a léčebné strategie v onkologii. Praha: Grada, 2010.

8. Novotný, J., Vítek, P., et al. Onkologie v klinické praxi. Praha: Mladá fronta, 2012.

9. Peren, TJ., et al. Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011, 365, p. 2484–2496.

10. Prat, J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch, 2012, 460, p. 237–249.

11. Ramakrishnan, S., et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis, 2005; 8(2), p. 169–182.

12. Rustin, GJ., Van der Burg, ME., Griffin, CL., et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV 05/EORTC 55955): a randomised trial. Lancet, 2010, 376, p. 1155–1163.

13. ÚZIS ČR, NOR ČR 2012. Novotvary 2009 ČR.

14. Vergote, IB., Joly, F., Katsaros, D., et al. Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCG study.J Clin Oncol., 2012, 30 (suppl; abstr LBA5000).

15. http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.42.0505

16. http://www.linkos.cz/informace-pro-praxi/modra-kniha/9-zhoubny-novotvar-ovarii-a-tuby- c56-57/